KOREA PHARMA Statistics

Total Valuation

KOREA PHARMA has a market cap or net worth of KRW 177.34 billion. The enterprise value is 161.43 billion.

Market Cap	177.34B
Enterprise Value	161.43B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	Dec 27, 2024

Share Statistics

KOREA PHARMA has 10.91 million shares outstanding. The number of shares has increased by 11.10% in one year.

Current Share Class	n/a
Shares Outstanding	10.91M
Shares Change (YoY)	+11.10%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	64.77%
Owned by Institutions (%)	0.05%
Float	3.84M

Valuation Ratios

The trailing PE ratio is 59.04.

PE Ratio	59.04
Forward PE	n/a
PS Ratio	2.22
PB Ratio	2.47
P/TBV Ratio	2.59
P/FCF Ratio	37.55
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 29.47, with an EV/FCF ratio of 34.18.

EV / Earnings	53.81
EV / Sales	2.02
EV / EBITDA	29.47
EV / EBIT	60.09
EV / FCF	34.18

Financial Position

The company has a current ratio of 4.23, with a Debt / Equity ratio of 0.31.

Current Ratio	4.23
Quick Ratio	2.89
Debt / Equity	0.31
Debt / EBITDA	3.07
Debt / FCF	4.72
Interest Coverage	1.66

Financial Efficiency

Return on equity (ROE) is 4.55% and return on invested capital (ROIC) is 2.66%.

Return on Equity (ROE)	4.55%
Return on Assets (ROA)	2.26%
Return on Invested Capital (ROIC)	2.66%
Return on Capital Employed (ROCE)	4.78%
Revenue Per Employee	595.51M
Profits Per Employee	22.39M
Employee Count	134
Asset Turnover	0.65
Inventory Turnover	2.28

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -28.53% in the last 52 weeks. The beta is 1.19, so KOREA PHARMA's price volatility has been higher than the market average.

Beta (5Y)	1.19
52-Week Price Change	-28.53%
50-Day Moving Average	15,743.60
200-Day Moving Average	17,363.55
Relative Strength Index (RSI)	54.43
Average Volume (20 Days)	28,496

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KOREA PHARMA had revenue of KRW 79.80 billion and earned 3.00 billion in profits. Earnings per share was 275.40.

Revenue	79.80B
Gross Profit	34.68B
Operating Income	4.47B
Pretax Income	2.12B
Net Income	3.00B
EBITDA	7.26B
EBIT	4.47B
Earnings Per Share (EPS)	275.40

Full Income Statement

Balance Sheet

The company has 38.23 billion in cash and 22.31 billion in debt, giving a net cash position of 15.91 billion or 1,459.17 per share.

Cash & Cash Equivalents	38.23B
Total Debt	22.31B
Net Cash	15.91B
Net Cash Per Share	1,459.17
Equity (Book Value)	71.77B
Book Value Per Share	6,580.57
Working Capital	58.37B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.80 billion and capital expenditures -1.07 billion, giving a free cash flow of 4.72 billion.

Operating Cash Flow	5.80B
Capital Expenditures	-1.07B
Free Cash Flow	4.72B
FCF Per Share	433.01

Full Cash Flow Statement

Margins

Gross margin is 43.46%, with operating and profit margins of 5.60% and 3.76%.

Gross Margin	43.46%
Operating Margin	5.60%
Pretax Margin	2.66%
Profit Margin	3.76%
EBITDA Margin	9.10%
EBIT Margin	5.60%
FCF Margin	5.92%

Dividends & Yields

This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.32%.

Dividend Per Share	50.00
Dividend Yield	0.32%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	18.18%
Buyback Yield	-11.10%
Shareholder Yield	-10.78%
Earnings Yield	1.69%
FCF Yield	2.66%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KOREA PHARMA has an Altman Z-Score of 5.01.

Altman Z-Score	5.01
Piotroski F-Score	n/a